Orphazyme A/S Overview
Latest P/E ratio for Orphazyme A/S: 22.61 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow22.61
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, ORPHY shows a P/E ratio of 22.61. That is below the Healthcare sector average of 27.42. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 27.42. Orphazyme A/S is at 22.61, which is lower that average. That is roughly 17.6% below the sector mean. Use the comparison chart on this page to see how ORPHY stacks up against individual peers as well.
Investors watch ORPHY's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Orphazyme A/S's latest reading is 22.61. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Orphazyme A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 22.61) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 27.42, while ORPHY is at 22.61. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
